生命科学资讯

The new rules of biopharma M&A: 4 trends driving dealmaking this year

ChenMed CEO warns against GLP-1s for seniors

Round three of IRA negotiations is expected to be ‘manageable’ for pharma

Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says

New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill

Eikon sets $274M goal for upcoming stock market debut

Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M

Oral Rogaine maker Veradermics looks to raise $181M from IPO

FDA asks court to pause Louisiana's abortion pill fight

Lilly bets on Seamless, delving further into genetic medicine for hearing loss

Lonza still intends to sell its capsules and health ingredients business

Lonza still intends to sell its capsules and health ingredients business - Endpoints News

Teva CEO says it has successfully transitioned into a biopharma company

Appointments and advancements for Jan. 28, 2026

Financings for Jan. 28, 2026

In the clinic for Jan. 28, 2026

Other news to note for Jan. 28, 2026

Regulatory actions for Jan. 28, 2026

Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

Halozyme buys a biotech startup; Cytokinetics launches heart drug